Abstracts tagged "spondyloarthritis"

Abstract Number: 0932 • ACR Convergence 2021
Sequential Treatment in Axial Spondyloarthritis – Real World Data from a Network of German Rheumatologists
Stefan Kleinert¹, Peter Bartz-Bazzanella², Cay Von der Decken³, Kirsten Karberg⁴, Florian Schuch⁵, Georg Gauler⁶, Patrick Wurth⁷, Susanna Späthling-Mestekemper⁸, Christoph Kuhn⁹, Fabian Proft¹⁰, Denis Poddubnyy¹¹, Mathias Englbrecht¹² and Wolfgang Vorbrüggen¹³, ¹Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, ²Rhein-Maas Klinikum, Wuerselen, Germany, ³Klinik für Internistische Rheumatologie, Rhein-Maas-Klinikum, Würselen, Germany, ⁴Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, ⁵Praxisgemeinschaft Rheumatologie-Nephrologie, Erlangen, Germany, ⁶rheumapraxis, Osnabrck, Germany, ⁷Rheumatologische Schwerpunktpraxis, Osnabrück, Germany, ⁸Rheumapraxis München, München, Germany, ⁹Praxis für Rheumatologie, Karlsruhe, Germany, Karlsruhe, Germany, ¹⁰Charité University Medicine Berlin, Berlin, Germany, ¹¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ¹²Freelance Healthcare Data Scientist, Eckental, Germany., Eckental, Germany, ¹³Verein zur Förderung der Rheumatologie e.V., Würselen, Germany
Background/Purpose: Increasing immunmodulatory treatment options are available for axial spondyloarthritis. Little is known about sequential treatment in clinical routine.Methods: The pseudonymized RHADAR database (Kleinert, S.…
Abstract Number: 1312 • ACR Convergence 2021
What Is the Optimal Screening Strategy for Early Recognition of Spondyloarthritis in Patients with Acute Anterior Uveitis?
Judith Rademacher¹, Hanna Müllner², Dominika Pohlmann³, Valeria Rios Rodriguez¹, Fabian Proft¹, Mikhail Protopopov¹, Susanne Lüders⁴, Burkhard Muche⁵, Laura Spiller¹, Anne-Katrin Weber², Sabrina Sron², Hildrun Haibel⁶, Uwe Pleyer³ and Denis Poddubnyy⁷, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Department of Ophthalmology, Berlin, Germany, ⁴Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁶Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: The diagnostic delay remains long in patients with spondyloarthritis (SpA), thus effective screening/referral strategies for early recognition are needed. Up to 40% of patients…
Abstract Number: 1776 • ACR Convergence 2021
Stakeholder Outcome Prioritization in the Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile Spondyloarthritis Trial
Pamela Weiss¹, Cora Sears¹, Timothy Brandon¹, Rui Xiao², Tory Aquino³, Kweli Archie¹, Aamena Hameed⁴, English Holland⁵, Miles Holland⁵, Asad Khan¹, Melanie Kohlheim⁶, Jennifer Leal⁷, Lynn Murphy⁸, Sean Murphy⁸, Antoinette Neu⁹, Emily Neu⁹, Jerome Neu⁹, Justin Neu⁹, Rachel Richmond¹⁰, Theresa Suplee¹¹, Dylan Suplee¹¹ and Christopher Forrest¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, ³Children's Hospital of Philadelphia, Aliquippa, PA, ⁴Children's Hospital of Philadelphia, Franklin Park, NJ, ⁵Children's Hospital of Philadelphia, Williamsburg, VA, ⁶Children's Hospital of Philadelphia, Granville, OH, ⁷Children's Hospital of Philadelphia, Columbus, OH, ⁸Children's Hospital of Philadelphia, Haddon Heights, NJ, ⁹Children's Hospital of Philadelphia, Sidney, OH, ¹⁰Children's Hospital of Philadelphia, Albuquerque, NM, ¹¹Children's Hospital of Philadelphia, Maple Shade, NJ
Background/Purpose: The BACK-OFF JSpA Study is a randomized pragmatic trial that will investigate different TNFi de-escalation strategies for children who have sustained asymptomatic disease. As…
Abstract Number: 0056 • ACR Convergence 2021
Peripheral Blood Immune Cell Profiling in Psoriatic Arthritis: Comparison of Patients with Healthy Controls
Lihi Eder¹, Darshini Ganatra² and Vinod Chandran³, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Heterogeneity in immune cell populations among patients with psoriatic arthritis (PsA) may determine disease expression and treatment response. The objective of this study was…
Abstract Number: 0364 • ACR Convergence 2021
Dose Tapering of TNF Inhibitors in Patients with Axial Spondyloarthritis in Routine Care – 2-year Clinical and MRI Outcomes and Predictors of Successful Tapering
Marie Wetterslev¹, Stylianos Georgiadis², Inge Juul Sørensen³, Susanne Juhl Pedersen², Sara Nysom Christiansen⁴, Merete Lund Hetland¹, Cecilie Heegaard Brahe², Mads Bakkegaard⁵, Anne Duer⁶, Mikael Boesen⁷, Kasper Kjærulf Gosvig⁸, Jakob Møllenbach Møller⁸, Niels Steen Krogh⁹, Bente Jensen⁵, Ole Rintek Madsen⁵, Jan Christensen⁵, Annette Hansen⁵, Jesper Nørregaard⁵, Henrik Røgind⁵ and Mikkel Ostergaard¹⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁵Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁶Department of Radiology, Rigshospitalet, Glostrup, Copenhagen, Denmark, ⁷Department of Radiology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁸Department of Radiology, Herlev and Gentofte Hospital, Copenhagen, Denmark, ⁹ZiteLab ApS, Copenhagen, Denmark, Frederiksberg, Denmark, ¹⁰Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark
Background/Purpose: In a 2-year follow-up study of patients with axial spondyloarthritis (axSpA) in clinical remission who tapered Tumor Necrosis Factor inhibitor (TNFi) treatment according to…
Abstract Number: 0381 • ACR Convergence 2021
How Do Clinical and Socioeconomic Factors Impact on Work Disability in Early Axial Spondyloarthritis? Five-year Data from the DESIR Cohort
Elena Nikiphorou¹, Annelies Boonen², Bruno Fautrel³, Pascal Richette⁴, Robert Landewé⁵, Désirée van der Heijde⁶ and Sofia Ramiro¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands, ³Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ⁴Lariboisiere Hospital, Paris, France, ⁵Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: There remains substantial unmet need to study work disability (WD) in early axSpA. Previous studies suggest that treatment interventions alone do not improve work…
Abstract Number: 0904 • ACR Convergence 2021
Data-driven Definitions Based on Inflammatory Lesions for a Positive MRI of the Spine Consistent with Axial Spondyloarthritis
Walter Maksymowych¹, Robert Lambert², Xenofon Baraliakos³, Susanne Pedersen⁴, Iris Eshed⁵, Ulrich Weber⁶, Pedro Machado⁷, Manouk de Hooge⁸, Joachim Sieper⁹, Stephanie Wichuk², Denis Poddubnyy¹⁰, Martin Rudwaleit¹¹, Robert Landewé¹², Désirée van der Heijde¹³ and Mikkel Ostergaard¹⁴, ¹Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ⁴Rigshospitalet, Center for Arthritis Research, Glostrup, Denmark, ⁵Sheba Medical Center, Ramat Gan, Israel, ⁶Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, ⁷Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁸Ghent University Hospital, Ghent, Belgium, ⁹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ¹⁰Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ¹¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ¹²Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ¹³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark
Background/Purpose: The ASAS definition of a positive MRI for inflammation in the spine (ASAS-MRI+) is intended for classification of patients as having axSpA but is…
Abstract Number: 0934 • ACR Convergence 2021
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-Radiographic Axial Spondylarthritis Patients Through 52 Weeks: Data from 3 Phase III, Randomized, Controlled Trials
Irene van der Horst-Bruinsma¹, Rebecca Bolce², Theresa Hunter³, David Sandoval Calderon², Danting Zhu², Vladimir Geneus², Jeffrey Lisse⁴, Soyi Liu-Leage⁵ and Marina Magrey⁶, ¹Amsterdam UMC, Amsterdam, Netherlands, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, ⁴Eli Lilly and Company, Tucson, AZ, ⁵Eli Lilly and Company, Neuilly sur Seine, France, ⁶Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease of the axial skeleton comprising two subtypes within the same spectrum: radiographic (r-axSpA) and non-radiographic (nr-axSpA).…
Abstract Number: 1313 • ACR Convergence 2021
The Impact of Comorbidities on Patients with Axial Spondyloarthritis: A Cluster Analysis
Seulkee Lee, Seonyoung Kang, Yeonghee Eun, Hyungjin Kim, Hoon-Suk Cha, Eun-Mi Koh and Jaejoon Lee, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Background/Purpose: Previous study using cluster analysis technique analyzed the association between comorbidities and various outcome measures in patients with axial spondyloarthritis (axSpA). Due to the…
Abstract Number: 1782 • ACR Convergence 2021
Disease Activity in Psoriatic Arthritis Patients with Enthesitis Across Different Therapies
Robert Chao¹, George Reed², Joel Kremer³ and Arthur Kavanaugh⁴, ¹Inova Health System, Fairfax, VA, ²University of Massachusetts, Worcester, MA, ³Department of Medicine, Center for Rheumatology, Albany Medical College, Albany, FL, ⁴University of California San Diego, La Jolla, CA
Background/Purpose: Evidence on the treatment of enthesitis, a common feature of psoriatic arthritis (PsA), is limited. This post-hoc, cross-sectional study examined if prevalent treatment choices…
Abstract Number: 0058 • ACR Convergence 2021
Effect of Anti-inflammatory Drugs on Intestinal Epithelial Damage and Bacterial Translocation in the Adjuvant-induced Arthritis Model
Sophie Hecquet¹, Perle Totoson², Maude Tournier², Clement Prati¹, Daniel Wendling¹, Céline Demougeot² and Frank Verhoeven¹, ¹Service de rhumatologie, CHU de Besançon, Besançon, France, ²PEPITE EA4267, FHU INCREASE, Bourgogne Franche-Comté University, Besançon, France
Background/Purpose: The intestine is no longer considered as an organ targeted by spondyloarthritis (SpA) but also an actor of the disease alongside environmental and immunological…
Abstract Number: 0365 • ACR Convergence 2021
A Cluster Analysis in Patients with Axial Spondyloarthritis Using TNFi Based on Clinical Characteristics
Seulkee Lee, Seonyoung Kang, Yeonghee Eun, Hyungjin Kim, Hoon-Suk Cha, Eun-Mi Koh and Jaejoon Lee, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Background/Purpose: Previous studies using cluster analysis technique in axial spondyloarthritis (axSpA) patients have consistently identified distinct groups of patients in terms of their clinical characteristics:…
Abstract Number: 0382 • ACR Convergence 2021
Six-year Results from the Esperanza Cohort: Evaluation of Clinical Features, Disease Activity Measures and Treatment Aspects in Axial and Peripheral Early Spondyloarthritis
Carolina Tornero¹, Victoria Navarro-Compán², raquel almodovar³, Cristina fernández-Carballido⁴, Azucena Hernández⁵, Beatriz Joven-Ibáñez⁶, Xavier Juanola⁷, M.Lourdes Ladehesa-Pineda⁸, José Ramón maneiro⁹, Antoni Juan Mas¹⁰, carlos Montilla¹¹, Manuel J Moreno¹², Mireia moreno¹³, José A. pinto¹⁴, juan Carlos Quevedo¹⁵, José Rosas¹⁶, Teresa Ruiz¹⁷, Jesús Sanz¹⁸ and Eugenio De Miguel¹⁹, ¹University Hospital La Paz, Madrid, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Hospital Universitario Fundación de Alcorcón, Madrid, Spain, ⁴H. San Juan, Alicante, Alicante, Spain, ⁵Hospital Virgen de la Salud, Toledo, Spain, ⁶University Hospital 12 de Octubre, Madrid, Spain, ⁷Hospital Universitari de Bellvitge, Barcelona, Spain, ⁸Hospital Universitario Reina Sofía, Córdoba, Spain, ⁹Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain, ¹⁰Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ¹¹Hospital Universitario de Salamanca, Salamanca, Spain, ¹²Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ¹³Parc Taulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí I3PT, Sabadell, Spain, ¹⁴Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain, ¹⁵Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain, ¹⁶Hospital Marina Baixa, Villajoyosa, ¹⁷Hospital de Sierrallana, Servicio de Reumatología, Torrelavega, Spain, ¹⁸Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹⁹Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Esperanza was a multicenter national health program developed to facilitate an early diagnosis of patients with Spondyloarthritis (SpA) in Spain. The main objective of…
Abstract Number: 0905 • ACR Convergence 2021
Artificial Neural Network for the Recognition of Active Inflammatory Changes Compatible with Axial Spondyloarthritis on Magnetic Resonance Imaging of Sacroiliac Joints
Denis Poddubnyy¹, Janis Vahldiek², Lisa Adams², Torsten Diekhoff², Fabian Proft², Mikhail Protopopov², Judith Rademacher², Valeria Rios Rodriguez², Murat Torgutalp², Stefan Niehues² and Keno Bressem², ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Active inflammatory changes in sacroiliac joints (SIJ) compatible with axial spondyloarthritis - axSpA (first of all, subchondral bone marrow edema – BME / osteitis)…
Abstract Number: 0935 • ACR Convergence 2021
Effects of Ixekizumab Treatment on Structural Changes in the Sacroiliac Joints Based on MRI Assessments at 16 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis
Walter Maksymowych¹, Xenofon Baraliakos², Robert Lambert³, Robert Landewé⁴, David Sandoval Calderon⁵, Hilde Carlier⁶, Jeffrey Lisse⁷, Xiaoqi Li⁵, Maja Hojnik⁵ and Mikkel Ostergaard⁸, ¹Department of Medicine, Division of Rheumatology at the University of Alberta, Alberta, Canada, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ³University of Alberta, Edmonton, AB, Canada, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Brussels, Belgium, ⁷Eli Lilly and Company, Tucson, AZ, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark
Background/Purpose: To evaluate the effect of treatment with ixekizumab versus placebo (PBO) on structural lesions in the sacroiliac joints (SIJ) at 16 weeks in patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].